Psychiatry Research
Volume 176, Issue 1 , Pages 13-16 , 30 March 2010

Obesity and smoking in patients with schizophrenia and normal controls: A case-control study

  • Konstantinos N. Fountoulakis

      Affiliations

    • 3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Greece
    • ,
  • Melina Siamouli

      Affiliations

    • Asklepeios Mental Hospital, Veroia, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30 2310 536439; fax: +30 2310 994622.
    • ,
  • Panagiotis Panagiotidis

      Affiliations

    • Depertment of Psychiatry, 424 General Military Hospital, Thessaloniki, Greece
    • ,
  • Stamatia Magiria

      Affiliations

    • School of Medicine, Aristotle University of Thessaloniki, Greece
    • ,
  • Sotiris Kantartzis

      Affiliations

    • Asklepeios Mental Hospital, Veroia, Greece
    • ,
  • Natalia Papastergiou

      Affiliations

    • School of Medicine, Aristotle University of Thessaloniki, Greece
    • ,
  • George Shoretsanitis

      Affiliations

    • School of Medicine, Aristotle University of Thessaloniki, Greece
    • ,
  • Eleonora Pantoula

      Affiliations

    • Asklepeios Mental Hospital, Veroia, Greece
    • ,
  • Katerina Moutou

      Affiliations

    • Asklepeios Mental Hospital, Veroia, Greece
    • ,
  • Evangelia Kouidi

      Affiliations

    • Laboratory of Sports Medicine, Aristotle University of Thessaloniki, Greece
    • ,
  • Symeon Deres

      Affiliations

    • Asklepeios Mental Hospital, Veroia, Greece

Received 5 December 2007 ,Revised 7 April 2008 ,Accepted 30 November 2008.

References 

  1. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry. 1999;60:215–220
  2. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophrenia Research. 2007;90:162–173
  3. Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garcia-Portilla MP, Fernandez I, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophrenia Research. 2003;62:77–88
  4. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalecne of the metabolic syndrome. Canadian Journal of Psychiatry. 2004;49:753–760
  5. Cohn TA, Remington G. Risk factors for coronary heart disease in longterm patients on antipsychotic drugs: high prevalence of syndrome X. Schizophrenia Research. 2003;60:353–354
  6. Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry. 2001;46:549–555
  7. Gilmore J. Body mass index and health. Health Reports. 1999;11:31–43
  8. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clinical Psychopharmacology. 2006;21:93–98
  9. Heiskanen T, Niskanen L, Lyytikainen R, Saarinrn PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry. 2003;64:575–579
  10. Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, et al. Dietary intake profile of patients with schizophrenia. Annals of Clinical Psychiatry. 2006;18:99–105
  11. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987–1996. Schizophrenia Research. 2002;55:277–284
  12. Japanese Ministry of Health Labour and Welfare . Health and Nutrition Survey in 2003. 2003;
  13. Kitabayashi Y, Narumoto J, Kitabayashi M, Fukui K. Body mass index among Japanese inpatients with schizophrenia. International Journal of Psychiatry in Medicine. 2006;36:93–102
  14. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research. 2005;80:19–32
  15. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research. 2005;80:9–18
  16. Saari K, Lindeman S, Viilo K, Isohanni M, Jarvelin MR, Lauren L, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 birth cohort study. Journal of Clinical Psychiatry. 2005;66:559–563
  17. Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Journal of Clinical Psychiatry. 2005;66:167–173
  18. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. International Journal of Obesity Related Metabolic Disorders. 2002;26:137–141
  19. Weiser M, Knobler H, Lubin G, Nahon D, Kravitz E, Caspi A, et al. Body mass index and future schizophrenia in Israeli male adolescents. Journal of Clinical Psychiatry. 2004;65:1546–1549
  20. Wing J, Babor T, Brugha T. SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry. 1990;47:589–593

PII: S0165-1781(08)00434-4

doi: 10.1016/j.psychres.2008.11.018

Psychiatry Research
Volume 176, Issue 1 , Pages 13-16 , 30 March 2010

Article Tools